Harwood Feffer LLP Announces Investigation of IRadimed Corporation

NEW YORK, Sept. 10, 2014 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is investigating potential claims against the board of directors of IRadimed Corporation ("IRadimed" or the "Company") (NASDAQ: IRMD), concerning whether the board has breached its fiduciary duties to shareholders.

On September 3, 2014, the Company disclosed that it has received a warning letter from the U.S. Food and Drug Administration resulting from an inspection of the Company's facility.  The warning letter also requested that the Company cease certain activities relating to certain of its products, including some of its infusion pumps.

Our investigation concerns whether the Company's board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing.

If you own IRadimed shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact:

Robert I. Harwood, Esq.
Daniella Quitt, Esq.
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
                          (212) 935-7400
Email:  dquitt@hfesq.com
Website:   http://www.hfesq.com

Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm. 

The law firm responsible for this advertisement is Harwood Feffer LLP (www.hfesq.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Logo - http://photos.prnewswire.com/prnh/20120215/MM54604LOGO

SOURCE Harwood Feffer LLP